Drugs / Emtricitabine/tenofovir disoproxil fumarate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06513312 | Oct 2024 → May 2026 overdue | — | Gilead Sciences | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emtricitabine/tenofovir disoproxil fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06513312 ↗ |
| Known as | F/TDF | “Emtricitabine/tenofovir disoproxil fumarate (F/TDF)” NCT06513312 ↗ |
| Route | Oral | “Administered orally” NCT06513312 ↗ |